Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 30NETWORK 10NIH 4INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 8Neoplasms 2Lymphoma, Extranodal NK-T-Cell 2Leukemia, Myeloid, Acute 2Lymphoproliferative Disorders 1Lymphoma 1Leukemia, Biphenotypic, Acute 1Leukemia 1Immunoproliferative Disorders 1Burkitt Lymphoma 1

Interventions

Cytarabine 21Imatinib Mesylate 20venetoclax 16Azacitidine 16nilotinib 15Cyclophosphamide 15fludarabine 13Dasatinib 12blinatumomab 10Rituximab 10quizartinib 7Gemtuzumab 7Daunorubicin 7ruxolitinib 6Drug Therapy 6Clofarabine 6Bendamustine Hydrochloride 6AP 1903 reagent 6ponatinib 5fludarabine phosphate 5Whole-Body Irradiation 5Vincristine 5Mycophenolic Acid 5Methotrexate 5Granulocyte Colony-Stimulating Factor 5Dexamethasone 5vosaroxin 4revumenib 4rasburicase 4forodesine 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Leukemia × pegaspargase × Clear all
NCT02723994 2026-03-11

A Phase 2 Study of Ruxolitinib With Chemotherapy in Children With Acute Lymphoblastic Leukemia

Incyte Corporation

Phase 2 Completed
171 enrolled
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Leukemia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡